A PHASE 3, MULTICENTER, OPEN-LABEL SAFETY STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF SAGE-718 IN PARTICIPANTS WITH HUNTINGTON'S DISEASE
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
Sage Therapeutics
Start Date
July 14, 2023
End Date
December 31, 2026
Administered By
Neurology, Movement Disorders
Awarded By
Sage Therapeutics
Start Date
July 14, 2023
End Date
December 31, 2026